199 related articles for article (PubMed ID: 33596988)
1. Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-2016.
Ramin C; Withrow DR; Davis Lynn BC; Gierach GL; Berrington de González A
Breast Cancer Res; 2021 Feb; 23(1):24. PubMed ID: 33596988
[TBL] [Abstract][Full Text] [Related]
2. Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer.
Brooks JD; John EM; Mellemkjaer L; Lynch CF; Knight JA; Malone KE; Reiner AS; Bernstein L; Liang X; Shore RE; Stovall M; ; Bernstein JL
Cancer Med; 2016 Nov; 5(11):3282-3291. PubMed ID: 27700016
[TBL] [Abstract][Full Text] [Related]
3. Race, ethnicity and risk of second primary contralateral breast cancer in the United States.
Watt GP; John EM; Bandera EV; Malone KE; Lynch CF; Palmer JR; Knight JA; Troester MA; Bernstein JL
Int J Cancer; 2021 Jun; 148(11):2748-2758. PubMed ID: 33544892
[TBL] [Abstract][Full Text] [Related]
4. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006.
Nichols HB; Berrington de González A; Lacey JV; Rosenberg PS; Anderson WF
J Clin Oncol; 2011 Apr; 29(12):1564-9. PubMed ID: 21402610
[TBL] [Abstract][Full Text] [Related]
5. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study.
Gao X; Fisher SG; Emami B
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1038-45. PubMed ID: 12829139
[TBL] [Abstract][Full Text] [Related]
6. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
[TBL] [Abstract][Full Text] [Related]
7. Second primary breast cancer occurrence according to hormone receptor status.
Kurian AW; McClure LA; John EM; Horn-Ross PL; Ford JM; Clarke CA
J Natl Cancer Inst; 2009 Aug; 101(15):1058-65. PubMed ID: 19590058
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study.
Langballe R; Mellemkjær L; Malone KE; Lynch CF; John EM; Knight JA; Bernstein L; Brooks J; Andersson M; Reiner AS; Liang X; Woods M; Concannon PJ; ; Bernstein JL
Breast Cancer Res; 2016 Jul; 18(1):65. PubMed ID: 27400983
[TBL] [Abstract][Full Text] [Related]
9. Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women.
Yoon TI; Kwak BS; Yi OV; Kim S; Um E; Yun KW; Shin HN; Lee S; Sohn G; Chung IY; Kim J; Ko BS; Lee JW; Son BH; Ahn SH; Kim HJ
Breast Cancer Res Treat; 2019 Feb; 173(3):657-665. PubMed ID: 30377870
[TBL] [Abstract][Full Text] [Related]
10. Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries.
Mezencev R; Švajdler M
Breast Cancer; 2017 May; 24(3):400-410. PubMed ID: 27502779
[TBL] [Abstract][Full Text] [Related]
11. The impact of in situ breast cancer and family history on risk of subsequent breast cancer events and mortality - a population-based study from Sweden.
Sackey H; Hui M; Czene K; Verkooijen H; Edgren G; Frisell J; Hartman M
Breast Cancer Res; 2016 Oct; 18(1):105. PubMed ID: 27756431
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for contralateral breast cancer in Chennai (Madras), India.
Gajalakshmi CK; Shanta V; Hakama M
Int J Epidemiol; 1998 Oct; 27(5):743-50. PubMed ID: 9839728
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
Saltzman BS; Malone KE; McDougall JA; Daling JR; Li CI
Breast Cancer Res Treat; 2012 Oct; 135(3):849-55. PubMed ID: 22903686
[TBL] [Abstract][Full Text] [Related]
14. Variation in the risk of radiation-related contralateral breast cancer by histology and estrogen receptor expression in SEER.
Neta G; Anderson WF; Gilbert E; Berrington A
Breast Cancer Res Treat; 2012 Feb; 131(3):1021-7. PubMed ID: 22015617
[TBL] [Abstract][Full Text] [Related]
15. Risk of contralateral second primary breast cancer according to hormone receptor status in Germany.
Rusner C; Wolf K; Bandemer-Greulich U; Engel J; Stegmaier C; Holleczek B; Schubert-Fritschle G; Tillack A; Stang A
Breast Cancer Res; 2014 Oct; 16(5):452. PubMed ID: 25277819
[TBL] [Abstract][Full Text] [Related]
16. Prediction and clinical utility of a contralateral breast cancer risk model.
Giardiello D; Steyerberg EW; Hauptmann M; Adank MA; Akdeniz D; Blomqvist C; Bojesen SE; Bolla MK; Brinkhuis M; Chang-Claude J; Czene K; Devilee P; Dunning AM; Easton DF; Eccles DM; Fasching PA; Figueroa J; Flyger H; García-Closas M; Haeberle L; Haiman CA; Hall P; Hamann U; Hopper JL; Jager A; Jakubowska A; Jung A; Keeman R; Kramer I; Lambrechts D; Le Marchand L; Lindblom A; Lubiński J; Manoochehri M; Mariani L; Nevanlinna H; Oldenburg HSA; Pelders S; Pharoah PDP; Shah M; Siesling S; Smit VTHBM; Southey MC; Tapper WJ; Tollenaar RAEM; van den Broek AJ; van Deurzen CHM; van Leeuwen FE; van Ongeval C; Van't Veer LJ; Wang Q; Wendt C; Westenend PJ; Hooning MJ; Schmidt MK
Breast Cancer Res; 2019 Dec; 21(1):144. PubMed ID: 31847907
[TBL] [Abstract][Full Text] [Related]
17. Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors Cohort.
Ramin C; Veiga LHS; Vo JB; Curtis RE; Bodelon C; Aiello Bowles EJ; Buist DSM; Weinmann S; Feigelson HS; Gierach GL; Berrington de Gonzalez A
Breast Cancer Res; 2023 May; 25(1):50. PubMed ID: 37138341
[TBL] [Abstract][Full Text] [Related]
18. Mortality after contralateral breast cancer in Denmark.
Langballe R; Frederiksen K; Jensen MB; Andersson M; Cronin-Fenton D; Ejlertsen B; Mellemkjær L
Breast Cancer Res Treat; 2018 Sep; 171(2):489-499. PubMed ID: 29948403
[TBL] [Abstract][Full Text] [Related]
19. Declining second primary ovarian cancer after first primary breast cancer.
Schonfeld SJ; Berrington de Gonzalez A; Visvanathan K; Pfeiffer RM; Anderson WF
J Clin Oncol; 2013 Feb; 31(6):738-43. PubMed ID: 23284037
[TBL] [Abstract][Full Text] [Related]
20. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.
Reiner AS; John EM; Brooks JD; Lynch CF; Bernstein L; Mellemkjær L; Malone KE; Knight JA; Capanu M; Teraoka SN; Concannon P; Liang X; Figueiredo JC; Smith SA; Stovall M; Pike MC; Haile RW; Thomas DC; Begg CB; Bernstein JL
J Clin Oncol; 2013 Feb; 31(4):433-9. PubMed ID: 23269995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
